Genmab A/S (LON:0MGB)
London · Delayed Price · Currency is GBP · Price in DKK | Market Cap | 10.96B +17.7% |
| Revenue (ttm) | 2.95B +20.7% |
| Net Income | 621.75M -27.7% |
| EPS | 9.93 -25.8% |
| Shares Out | n/a |
| PE Ratio | 17.62 |
| Forward PE | 17.49 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 22,623 |
| Open | 1,609.50 |
| Previous Close | 1,639.00 |
| Day's Range | 1,525.50 - 1,612.00 |
| 52-Week Range | 1,276.25 - 2,256.00 |
| Beta | 0.70 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 7, 2026 |
About Genmab
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell n... [Read more]
Financial Performance
In 2025, Genmab's revenue was $3.72 billion, an increase of 19.19% compared to the previous year's $3.12 billion. Earnings were $963.00 million, a decrease of -15.00%.
Financial numbers in USD Financial StatementsNews
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
Company Announcement COPENHAGEN, Denmark; May 29, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this...
Genmab assumed with a Buy at Truist
Truist analyst Gregory Renza assumed coverage of Genmab (GMAB) with a Buy rating and a price target of $40, down from $48. The firm is positive on the company’s transition…
Genmab A/S: Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress
Twenty-three abstracts will highlight the versatility and strength of Genmab's portfolio and pipeline, including data from the comprehensive epcoritamab development program, including 4 oral prese...
Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress
Media Release COPENHAGEN, Denmark; May 21, 2026 Twenty-three abstracts will highlight the versatility and strength of Genmab's portfolio and pipeline, including data from the comprehensive epcoritamab...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement COPENHAGEN, Denmark; May 12, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 2,346 shares as a consequence of the exercise of employee warrants. The increase i...
Genmab price target lowered to DKK 2,250 from DKK 2,400 at Deutsche Bank
Deutsche Bank analyst Emmanuel Papadakis lowered the firm’s price target on Genmab (GMAB) to DKK 2,250 from DKK 2,400 and keeps a Buy rating on the shares. Published first on…
Genmab (GMAB) Reports Significant Shareholding by Orbis Investment Management
Genmab (GMAB) Reports Significant Shareholding by Orbis Investment Management
Genmab announces 5.08% stake by Orbis Investment
Genmab (GMAB) announces that Orbis Investment Management has informed the company that through shares, as of May 8, it controlled the voting rights to 3,166,357 shares in Genmab, which amounts…
Genmab price target lowered to $33 from $34 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Genmab (GMAB) to $33 from $34 and keeps an Equal Weight rating on the shares.
Genmab reports Q1 operating profit $180M, consensus $172.7M
Reports Q1 revenue $896M, consensus $901.1M. “We made tangible progress in the first quarter as we continue to integrate Merus and advance our late-stage portfolio – EPKINLY, Rina-S and petosemtamab.
Genmab maintains FY26 guidance
Genmab (GMAB) is maintaining its 2026 financial guidance published February 17, the company stated with its Q1 report.
Genmab Earnings Call Transcript: Q1 2026
Q1 2026 saw 25% revenue growth and 23% operating profit growth, led by strong EPKINLY and TIVDAK sales. Rina-S phase III enrollment finished early, supporting accelerated filings, while guidance for 14% revenue growth and substantial profitability in 2026 was reaffirmed.
Genmab Quarterly report: Q1 2026
Genmab has published its Q1 2026 quarterly earnings report on May 7, 2026.
Genmab Earnings release: Q1 2026
Genmab released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Genmab Slides: Q1 2026
Genmab has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Genmab A/S Reveals Drop In Q1 Income
BRUSSELS (dpa-AFX) - Genmab A/S (GMAB) reported a profit for first quarter that Dropped, from the same period last yearThe company's bottom line came in at $53 million, or $0.83 per share. This co...
Genmab Announces Financial Results for the First Quarter of 2026
May 7, 2026 Copenhagen, Denmark; Interim Report for the Three Months Ended March 31, 2026 Highlights Genmab revenue increased 25% compared to the first three months of 2025 , to $896 million FDA appro...
What To Expect From Genmab AS (GMAB) Q1 2026 Earnings
What To Expect From Genmab AS (GMAB) Q1 2026 Earnings
Genmab price target lowered to $38 from $40 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Genmab (GMAB) to $38 from $40 and keeps a Buy rating on the shares. Given Pfizer’s results from the MagnetisMM-5 trial, the…
Genmab upgraded to Outperform from Neutral at BNP Paribas
BNP Paribas upgraded Genmab (GMAB) to Outperform from Neutral with a DKK 2,400 price target
Genmab upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Rajan Sharma upgraded Genmab (GMAB) to Buy from Neutral with a $30.50 price target The firm sees a “catalyst-rich” 2026 for Genmab and a favorable risk/reward for…
Genmab A/S Share Capital Reduction
Company Announcement COPENHAGEN, Denmark; April 17, 2026 – Genmab A/S (Nasdaq: GMAB) At Genmab A/S' Annual General Meeting on March 19, 2026, it was decided to reduce the Company's share capital with ...
Major Shareholder Announcement
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; April 14, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets...
Genmab reports Darzalex Q1 worldwide sales $3.964B
Genmab (GMAB) announced that worldwide net trade sales of DARZALEX, or daratumumab, including sales of the subcutaneous, or SC, product, daratumumab and hyaluronidase-fihj, sold under the tradename DA...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026
Company Announcement Net sales of DARZALEX ® in the first quarter of 2026 totaled USD 3,964 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen B...